[go: up one dir, main page]

WO2013150167A3 - Micro-rna expression model as an indicator of survival of patients affected by metastatic colorectal cancer - Google Patents

Micro-rna expression model as an indicator of survival of patients affected by metastatic colorectal cancer Download PDF

Info

Publication number
WO2013150167A3
WO2013150167A3 PCT/ES2013/070218 ES2013070218W WO2013150167A3 WO 2013150167 A3 WO2013150167 A3 WO 2013150167A3 ES 2013070218 W ES2013070218 W ES 2013070218W WO 2013150167 A3 WO2013150167 A3 WO 2013150167A3
Authority
WO
WIPO (PCT)
Prior art keywords
survival
colorectal cancer
metastatic colorectal
indicator
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2013/070218
Other languages
English (en)
French (fr)
Other versions
WO2013150167A2 (es
Inventor
Rocío GARCÍA CARBONERO
Luis Gonzalo PAZ-ARES
Sonia MOLINA PINELO
Amancio Carnero Moya
Rocio SUAREZ BELTRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Servicio Andaluz de Salud
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Sevilla, Servicio Andaluz de Salud filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of WO2013150167A2 publication Critical patent/WO2013150167A2/es
Publication of WO2013150167A3 publication Critical patent/WO2013150167A3/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

El cáncer colorrectal está entre las causas más comunes de muerte relacionada con cáncer en el mundo occidental y entre los tumores malignos más comunes en el mundo. El tratamiento del cáncer colorrectal metastásico comprende normalmente quimioterapia, aunque el éxito de la terapia varía significativamente entre los pacientes. Existe de esta manera una necesidad de predecir la respuesta y las índices de supervivencia de los pacientes individuales. La presente invención proporciona procedimientos y herramientas que representan un avance mayor. En particular, la invención informa acerca de un conjunto de microARN que son útiles en los procedimientos de predecir la supervivencia de pacientes tratadoscon quimioterapia. Las herramientas aplicables en dichos procedimientos de predicción son también parte de la invención.
PCT/ES2013/070218 2012-04-03 2013-04-03 Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico Ceased WO2013150167A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230513 2012-04-03
ESP201230513 2012-04-03

Publications (2)

Publication Number Publication Date
WO2013150167A2 WO2013150167A2 (es) 2013-10-10
WO2013150167A3 true WO2013150167A3 (es) 2014-01-30

Family

ID=48626460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2013/070218 Ceased WO2013150167A2 (es) 2012-04-03 2013-04-03 Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico

Country Status (1)

Country Link
WO (1) WO2013150167A2 (es)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221609A1 (en) * 2006-02-28 2009-09-03 Pfizer Products, Inc. Gene Predictors of Response to Metastatic Colorectal Chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
KR20090003178A (ko) 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
WO2009111643A2 (en) 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221609A1 (en) * 2006-02-28 2009-09-03 Pfizer Products, Inc. Gene Predictors of Response to Metastatic Colorectal Chemotherapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Cancer MicroRNA qPCR Array with QuantiMir(TM): User manual", 1 January 2007 (2007-01-01), XP055080102, Retrieved from the Internet <URL:http://www.systembio.com/downloads/Manual_Cancer_miR_qPCR_Array_v2.pdf> [retrieved on 20130919] *
ANONYMOUS: "Taqman array human MicroRNA Cards", INTERNET CITATION, 2010, pages 1 - 2, XP002672200, Retrieved from the Internet <URL:http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_054742.pdf> [retrieved on 20120323] *
GIUSEPPINA DELLA VITTORIA SCARPATI ET AL: "A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGYBIOLOGYPHYSICS, vol. 83, no. 4, 13 December 2011 (2011-12-13), pages 1113 - 1119, XP055080148, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2011.09.030 *
J V SCHOU ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J CLIN ONCOL, 1 February 2011 (2011-02-01), XP055080168, Retrieved from the Internet <URL:http://meetinglibrary.asco.org/print/571892> [retrieved on 20130919] *
K. LIU ET AL: "Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 39, no. 6, 1 December 2011 (2011-12-01), pages 2288 - 2295, XP055080147, ISSN: 0300-0605, DOI: 10.1177/147323001103900626 *
KEN KUROKAWA ET AL: "Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROENTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 March 2012 (2012-03-01), pages 883 - 895, XP035100951, ISSN: 1435-5922, DOI: 10.1007/S00535-012-0547-6 *
N KNIJN: "Current Issues in the Targeted Therapy of Advanced Colorectal Cancer", DISCOVERY MEDICINE, 10 April 2010 (2010-04-10), XP055080024, Retrieved from the Internet <URL:http://www.discoverymedicine.com/Nikki-Knijn/2010/04/10/current-issues-in-the-targeted-therapy-of-advanced-colorectal-cancer/> [retrieved on 20130919] *
ROLF SØKILDE ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 February 2009 (2009-02-23), XP055080160, Retrieved from the Internet <URL:http://www.exiqon.com/ls/Documents/Scientific/15_20b_EDR_V1_update_jan09_ HI.pdf> [retrieved on 20130919] *
SCHETTER AARON J ET AL: "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 299, no. 4, 30 January 2008 (2008-01-30), pages 425 - 436, XP002529936, ISSN: 0098-7484, DOI: 10.1001/JAMA.299.4.425 *
TORBEN FRÖSTRUP HANSEN ET AL: "The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 8 March 2012 (2012-03-08), pages 83, XP021118144, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-83 *
Y DONG ET AL: "MicroRNA dysregulation in colorectal cancer: a clinical perspective", BRITISH JOURNAL OF CANCER, vol. 104, no. 6, 1 March 2011 (2011-03-01), pages 893 - 898, XP055080175, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.57 *

Also Published As

Publication number Publication date
WO2013150167A2 (es) 2013-10-10

Similar Documents

Publication Publication Date Title
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2013006495A3 (en) Methods of predicting prognosis in cancer
EP3119908A4 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
IL238015A0 (en) Methods to prevent cancer metastases, treatment and prognosis of cancer and identification of potential metastasis inhibitors
MY193914A (en) Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
MY174562A (en) Conjugated antibodies against ly75 for the treatment of cancer
WO2014145751A3 (en) Targeted therapies for cancer
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
EP3011055A4 (en) Classification system, methods and kit for classifying. predicting and treating breast cancer
WO2013025322A3 (en) Marker-based prognostic risk score in liver cancer
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
HK1202156A1 (en) Methods for increasing efficacy of cd37-based therapy
NZ712023A (en) Caix stratification based cancer treatment
MX365464B (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
HK1251171A1 (zh) 肿瘤生物标志物及其应用
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
GB2523693A (en) Materials and methods for determining susceptibility or predisposition to cancer
MX2015013197A (es) Biomarcadores de la respuesta farmacodinamica tumoral.
CA3111702C (en) METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2013150167A3 (es) Micro-rna expression model as an indicator of survival of patients affected by metastatic colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13729032

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13729032

Country of ref document: EP

Kind code of ref document: A2